NASDAQ:FLGT - Fulgent Genetics Stock Price, Forecast & News

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Fulgent Genetics Inc (NASDAQ:FLGT) announced its quarterly earnings data on Monday, August, 6th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.03) by $0.02. The firm earned $5.40 million during the quarter, compared to the consensus estimate of $4.97 million. Fulgent Genetics had a negative return on equity of 0.16% and a negative net margin of 3.52%. View Fulgent Genetics' Earnings History.

Fulgent Genetics is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Fulgent Genetics.

Fulgent Genetics will be holding an earnings conference call on Tuesday, March 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

2 equities research analysts have issued 12 month price objectives for Fulgent Genetics' shares. Their forecasts range from $12.30 to $12.30. On average, they expect Fulgent Genetics' share price to reach $12.30 in the next year. This suggests that the stock has a possible downside of 35.3%. View Analyst Price Targets for Fulgent Genetics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fulgent Genetics.

News stories about FLGT stock have trended very negative on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Fulgent Genetics earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Fulgent Genetics.

Fulgent Genetics saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 289,700 shares, an increase of 33.2% from the December 31st total of 217,500 shares. Based on an average daily volume of 315,600 shares, the days-to-cover ratio is presently 0.9 days. Approximately 3.7% of the shares of the company are short sold. View Fulgent Genetics' Current Options Chain.

Some companies that are related to Fulgent Genetics include Veracyte (VCYT), CareDx (CDNA), RadNet (RDNT), Castle Biosciences (CSTL), Personalis (PSNL), Centogene (CNTG), DermTech (DMTK), Anpac Bio-Medical Science (ANPC), Enzo Biochem (ENZ), Celcuity (CELC), Psychemedics (PMD), Miragen Therapeutics (MGEN), PotNetwork (POTN), Biocept (BIOC) and Cancer Genetics (CGIX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Baidu (BIDU), Baozun (BZUN), Canopy Growth (CGC), Advanced Micro Devices (AMD), DexCom (DXCM), Zynerba Pharmaceuticals (ZYNE) and AbbVie (ABBV).

(FLGT) raised $60 million in an initial public offering on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Fulgent Genetics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Driehaus Capital Management LLC (2.94%), Old West Investment Management LLC (2.82%), Raymond James Trust N.A. (2.24%), Essex Investment Management Co. LLC (1.14%), EAM Investors LLC (1.05%) and Cadence Capital Management LLC (0.87%). Company insiders that own Fulgent Genetics stock include Ming Hsieh and Paul Kim. View Institutional Ownership Trends for Fulgent Genetics.

FLGT stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Raymond James Trust N.A., Mutual Advisors LLC, Old West Investment Management LLC and Alambic Investment Management L.P.. View Insider Buying and Selling for Fulgent Genetics.

FLGT stock was purchased by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Cadence Capital Management LLC, EAM Global Investors LLC, Acadian Asset Management LLC, EAM Investors LLC, Essex Investment Management Co. LLC, Wedge Capital Management L L P NC and Geode Capital Management LLC. View Insider Buying and Selling for Fulgent Genetics.

Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FLGT stock can currently be purchased for approximately $19.00.

Fulgent Genetics has a market capitalization of $355.49 million and generates $21.36 million in revenue each year. The company earns $-5,610,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Fulgent Genetics employs 123 workers across the globe.View Additional Information About Fulgent Genetics.

The official website for Fulgent Genetics is http://www.fulgentgenetics.com/.

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE SUITE 205, TEMPLE CITY CA, 91780. The company can be reached via phone at 626-350-0537 or via email at [email protected]